Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.60 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.50 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797106 | 0.91 | CRBN (0.63) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL30797273 | 0.90 | CRBN (0.64) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL30797127 | 0.89 | CRBN (0.61) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL30797271 | 0.88 | CRBN (0.57) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL30797277 | 0.88 | CRBN (0.57) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL30797158 | 0.88 | CRBN (0.57) | CRBNCSNK1A1IKZF2IKZF1DDB1 | |
| SCHEMBL30797171 | 0.86 | CRBN (0.57) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL30797274 | 0.86 | CRBN (0.57) | CRBNCSNK1A1IKZF2IKZF1BRD4 | |
| SCHEMBL30797107 | 0.85 | CRBN (0.58) | CRBNIKZF2 | |
| SCHEMBL30797297 | 0.84 | CRBN (0.62) | CRBNIKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |